Zimislecel is named as an intervention in 2 current clinical trials in our USA, Canada, UK, Germany, France, Italy, Netherlands, Switzerland and Norway registers. 2 are recruiting patients now. All registered phases are Phase 3. The lead sponsor is Vertex Pharmaceuticals Incorporated. The most-studied condition is Diabetes Mellitus, Type 1.
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314904, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
NCT04786262 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
|
Phase 3 | Recruiting | Vertex Pharmaceuticals Incorporated | UK, USA, Germany, France, Italy, Netherlands, Switzerland, Norway, Canada |
|
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
NCT06832410 · ClinicalTrials.gov ↗ · Type 1 Diabetes, Kidney Transplant
|
Phase 3 | Recruiting | Vertex Pharmaceuticals Incorporated | USA, Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Vertex Pharmaceuticals Incorporated | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA, Canada, UK, Germany, France, Italy, Netherlands, Switzerland and Norway registers name Zimislecel (also registered as VX-880) as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA, 2 with sites in Canada, 1 with sites in UK, 1 with sites in Germany, 1 with sites in France, 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Switzerland and 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Vertex Pharmaceuticals Incorporated. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Zimislecel works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Zimislecel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Zimislecel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.